Samsung Bioepis’s Biosimilar Enbrel ‘Substitutable’ In Australia As Pfizer Patent Case Is Rebuffed

 
• By Ian Schofield
  
Magnifying glass focusing on Australia
Biosimilar etanercept is the latest biosimilar to be substitutable in Australia

More from Biosimilars

More from Biosimilars & Generics